Details of the Drug Combination

General Information of Drug Combination (ID: DCA8Z72)

Drug Combination Name
Sulindac Idarubicin
Indication
Disease Entry Status REF
Glioblastoma? Investigative [1]
Component Drugs Sulindac   DM2QHZU Idarubicin   DMM0XGL
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: T98G
Zero Interaction Potency (ZIP) Score: 21.72
Bliss Independence Score: 21.72
Loewe Additivity Score: 10.82
LHighest Single Agent (HSA) Score: 10.82

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sulindac
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [2]
Bursitis N.A. Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Colon cancer 2B90.Z Investigative [2]
Sulindac Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aldose reductase (AKR1B1) TTFBNVI ALDR_HUMAN Inhibitor [10]
------------------------------------------------------------------------------------
Sulindac Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Sulindac Interacts with 201 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Polyunsaturated fatty acid lipoxygenase ALOX15 (ALOX15) OT0RTR7M LOX15_HUMAN Increases Activity [12]
Arylamine N-acetyltransferase 1 (NAT1) OTCCNQ3H ARY1_HUMAN Decreases Expression [13]
Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial (GATD3) OTBQRU82 GAL3B_HUMAN Decreases Expression [6]
Endosome/lysosome-associated apoptosis and autophagy regulator family member 2 (ELAPOR2) OTL628I1 ELAP2_HUMAN Increases Expression [6]
Protocadherin-17 (PCDH17) OTRK0M05 PCD17_HUMAN Decreases Expression [6]
Aurora kinase A (AURKA) OTMX0HYT AURKA_HUMAN Decreases Expression [6]
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (ATP2A1) OT959A3A AT2A1_HUMAN Decreases Expression [6]
NPC intracellular cholesterol transporter 1 (NPC1) OTRIPICX NPC1_HUMAN Increases Expression [6]
T-box transcription factor TBX3 (TBX3) OTM64N7K TBX3_HUMAN Increases Expression [6]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Increases Expression [6]
Origin recognition complex subunit 4 (ORC4) OT3ACTST ORC4_HUMAN Decreases Expression [6]
Bromodomain-containing protein 4 (BRD4) OT2Y2TCW BRD4_HUMAN Decreases Expression [6]
Transmembrane protein 127 (TMEM127) OTYHUXC1 TM127_HUMAN Increases Expression [6]
Hyaluronan mediated motility receptor (HMMR) OT4M0JTZ HMMR_HUMAN Decreases Expression [6]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Increases Expression [6]
Ribonuclease pancreatic (RNASE1) OTKZ7CO9 RNAS1_HUMAN Decreases Expression [6]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Increases Expression [6]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Increases Expression [6]
Calmodulin-1 (CALM2) OTNYA92F CALM1_HUMAN Decreases Expression [6]
Lysosomal acid phosphatase (ACP2) OTLPA1LJ PPAL_HUMAN Increases Expression [6]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Increases Expression [6]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [6]
Protein C-ets-1 (ETS1) OT4LVGDN ETS1_HUMAN Increases Expression [6]
Integrin alpha-2 (ITGA2) OTPFL017 ITA2_HUMAN Increases Expression [6]
Transcription factor JunD (JUND) OTNKACJD JUND_HUMAN Increases Expression [6]
Cyclic AMP-dependent transcription factor ATF-3 (ATF3) OTC1UOHP ATF3_HUMAN Increases Expression [6]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [6]
Casein kinase II subunit alpha' (CSNK2A2) OT7MA2LV CSK22_HUMAN Increases Expression [6]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [6]
DNA excision repair protein ERCC-5 (ERCC5) OTQAKFJM ERCC5_HUMAN Decreases Expression [6]
High affinity cationic amino acid transporter 1 (SLC7A1) OTR2ZVA8 CTR1_HUMAN Increases Expression [6]
RAC-beta serine/threonine-protein kinase (AKT2) OTBB632K AKT2_HUMAN Decreases Expression [6]
Biotin--protein ligase (HLCS) OTPDUX30 BPL1_HUMAN Decreases Expression [6]
Plexin-A3 (PLXNA3) OTMZIBVG PLXA3_HUMAN Increases Expression [6]
Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 (NDST2) OT21PY3J NDST2_HUMAN Decreases Expression [6]
Small ubiquitin-related modifier 3 (SUMO3) OTTUJQJ1 SUMO3_HUMAN Decreases Expression [6]
Histone H4 (H4C1) OTB71W46 H4_HUMAN Increases Expression [6]
Casein kinase II subunit alpha (CSNK2A1) OT9T8WQM CSK21_HUMAN Decreases Expression [6]
Polycystin-1 (PKD1) OT5ALRZ5 PKD1_HUMAN Increases Expression [6]
Transcription initiation factor IIB (GTF2B) OTAH5NSO TF2B_HUMAN Increases Expression [6]
Cyclin-dependent kinase 3 (CDK3) OT2GP6RL CDK3_HUMAN Decreases Expression [6]
Cdc42 effector protein 1 (CDC42EP1) OTT525WA BORG5_HUMAN Increases Expression [6]
Growth factor receptor-bound protein 10 (GRB10) OTCKXGRC GRB10_HUMAN Increases Expression [6]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Increases Expression [6]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Increases Expression [6]
Dihydropyrimidinase (DPYS) OTLTUIVL DPYS_HUMAN Increases Expression [6]
Four and a half LIM domains protein 2 (FHL2) OT0OAYWT FHL2_HUMAN Increases Expression [6]
Endoplasmic reticulum membrane sensor NFE2L1 (NFE2L1) OT1QHOS2 NF2L1_HUMAN Increases Expression [6]
Kinesin-like protein KIF14 (KIF14) OTXHT4JM KIF14_HUMAN Increases Expression [6]
Syntaxin-binding protein 2 (STXBP2) OTX8GUC4 STXB2_HUMAN Increases Expression [6]
Nuclear factor interleukin-3-regulated protein (NFIL3) OTQH9HM3 NFIL3_HUMAN Increases Expression [6]
Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2) OTJ8LX4N PCKGM_HUMAN Increases Expression [6]
TBC1 domain family member 10B (TBC1D10B) OT5MVCI5 TB10B_HUMAN Increases Expression [6]
Migration and invasion-inhibitory protein (MIIP) OT79EXZ7 MIIP_HUMAN Increases Expression [6]
Cyclin-J (CCNJ) OTCR4WVV CCNJ_HUMAN Decreases Expression [6]
OTU domain-containing protein 1 (OTUD1) OTE6O5XB OTUD1_HUMAN Increases Expression [6]
Tensin-3 (TNS3) OTPG2D8Z TENS3_HUMAN Decreases Expression [6]
F-box only protein 42 (FBXO42) OTHPN53C FBX42_HUMAN Increases Expression [6]
Metal transporter CNNM4 (CNNM4) OTUXJRM1 CNNM4_HUMAN Increases Expression [6]
Ankyrin repeat domain-containing protein 11 (ANKRD11) OTV0V70M ANR11_HUMAN Increases Expression [6]
La-related protein 4 (LARP4) OTB10IJH LARP4_HUMAN Increases Expression [6]
LIM domain-binding protein 1 (LDB1) OT20EAPR LDB1_HUMAN Increases Expression [6]
Transmembrane protein adipocyte-associated 1 (TPRA1) OTL61503 TPRA1_HUMAN Increases Expression [6]
Mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3) OTNJX38T M4K3_HUMAN Increases Expression [6]
UPF0690 protein C1orf52 (C1ORF52) OT8RQW3W CA052_HUMAN Increases Expression [6]
Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (LFNG) OTPSUBN2 LFNG_HUMAN Increases Expression [6]
Osteoclast-stimulating factor 1 (OSTF1) OT8D7CDO OSTF1_HUMAN Increases Expression [6]
Caveolae-associated protein 3 (CAVIN3) OTOLBK79 CAVN3_HUMAN Increases Expression [6]
Sorting nexin-21 (SNX21) OT8O6909 SNX21_HUMAN Increases Expression [6]
Arrestin domain-containing protein 3 (ARRDC3) OTAKW7R9 ARRD3_HUMAN Increases Expression [6]
Splicing factor ESS-2 homolog (ESS2) OTZ08VCZ ESS2_HUMAN Increases Expression [6]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Expression [6]
Histone-lysine N-methyltransferase EHMT2 (EHMT2) OTC4DWB6 EHMT2_HUMAN Decreases Expression [6]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [6]
Sodium-coupled neutral amino acid symporter 2 (SLC38A2) OTALABSK S38A2_HUMAN Increases Expression [6]
Mediator of RNA polymerase II transcription subunit 15 (MED15) OT0D0JVD MED15_HUMAN Increases Expression [6]
Pleckstrin homology domain-containing family F member 1 (PLEKHF1) OT9OL16U PKHF1_HUMAN Increases Expression [6]
Sialidase-1 (NEU1) OTH9BY8Y NEUR1_HUMAN Increases Expression [6]
Translin-associated protein X (TSNAX) OTZ9SGWB TSNAX_HUMAN Decreases Expression [6]
Copine-1 (CPNE1) OTH5YKSL CPNE1_HUMAN Decreases Expression [6]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [6]
Allograft inflammatory factor 1-like (AIF1L) OTDEOB80 AIF1L_HUMAN Decreases Expression [6]
Ferroptosis suppressor protein 1 (AIFM2) OT57XWXO FSP1_HUMAN Increases Expression [6]
Transmembrane emp24 domain-containing protein 9 (TMED9) OTYGAQS0 TMED9_HUMAN Decreases Expression [6]
E3 ubiquitin-protein ligase RNF26 (RNF26) OTPXA60S RNF26_HUMAN Decreases Expression [6]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Increases Expression [6]
Sorting nexin-25 (SNX25) OT8JY8M1 SNX25_HUMAN Increases Expression [6]
tRNA dimethylallyltransferase (TRIT1) OTCU9FS5 MOD5_HUMAN Decreases Expression [6]
PDZ and LIM domain protein 7 (PDLIM7) OTAZVODU PDLI7_HUMAN Increases Expression [6]
Phosphatidylinositol polyphosphate 5-phosphatase type IV (INPP5E) OTJF2AZ9 INP5E_HUMAN Increases Expression [6]
Transmembrane protein 39A (TMEM39A) OTRT51D9 TM39A_HUMAN Increases Expression [6]
Arginine and glutamate-rich protein 1 (ARGLU1) OTRVRZ4Z ARGL1_HUMAN Increases Expression [6]
SUN domain-containing protein 2 (SUN2) OT2IQJUC SUN2_HUMAN Decreases Expression [6]
B-cell receptor-associated protein 29 (BCAP29) OTLUBG86 BAP29_HUMAN Increases Expression [6]
Proton-coupled zinc antiporter SLC30A1 (SLC30A1) OTY8J0S4 ZNT1_HUMAN Increases Expression [6]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Decreases Activity [14]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Decreases Activity [14]
Solute carrier family 22 member 6 (SLC22A6) OTKRCBVM S22A6_HUMAN Decreases Activity [14]
Organic anion transporter 7 (SLC22A9) OTO4BJCC S22A9_HUMAN Decreases Activity [14]
Solute carrier family 22 member 11 (SLC22A11) OTAJLNJZ S22AB_HUMAN Decreases Activity [14]
Solute carrier family 22 member 7 (SLC22A7) OTKTNH1W S22A7_HUMAN Decreases Activity [14]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Increases Expression [15]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [16]
Sulfotransferase 1E1 (SULT1E1) OTGPJ517 ST1E1_HUMAN Decreases Activity [17]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [7]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [7]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Localization [7]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [7]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Decreases Activity [18]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Decreases Activity [18]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Decreases Activity [18]
Ladinin-1 (LAD1) OT6YGTVX LAD1_HUMAN Increases Expression [19]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [20]
Inhibitor of nuclear factor kappa-B kinase subunit beta (IKBKB) OT9RDS3H IKKB_HUMAN Decreases Activity [21]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [22]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Increases Expression [23]
Serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) OTY9R6FZ ERN1_HUMAN Increases Expression [24]
DNA fragmentation factor subunit beta (DFFB) OTPBW5N5 DFFB_HUMAN Affects Localization [25]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [25]
Renin (REN) OT52GZR2 RENI_HUMAN Decreases Activity [26]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Affects Expression [27]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [28]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [29]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [30]
HLA class I histocompatibility antigen, B alpha chain (HLA-B) OTNXFWY2 HLAB_HUMAN Affects Expression [31]
Apolipoprotein C-III (APOC3) OTW3520C APOC3_HUMAN Decreases Secretion [24]
Ferritin heavy chain (FTH1) OT6IFS0O FRIH_HUMAN Increases Expression [8]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Secretion [24]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [32]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Decreases Expression [33]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [34]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Expression [35]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Decreases Expression [24]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Expression [19]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Affects Expression [27]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [36]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Activity [32]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Affects Expression [27]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [37]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Expression [8]
Transcription factor 4 (TCF4) OTB9ASTK ITF2_HUMAN Decreases Activity [38]
Neuromodulin (GAP43) OT2OTGGV NEUM_HUMAN Affects Expression [27]
Cyclic AMP-dependent transcription factor ATF-6 alpha (ATF6) OTAFHAVI ATF6A_HUMAN Increases Expression [24]
Nuclear factor NF-kappa-B p105 subunit (NFKB1) OTNRRD8I NFKB1_HUMAN Decreases Activity [39]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [34]
Galanin peptides (GAL) OTB3VPTO GALA_HUMAN Affects Expression [27]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [40]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Expression [34]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Activity [41]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Decreases Phosphorylation [42]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [36]
Protein-lysine 6-oxidase (LOX) OT1C2HIU LYOX_HUMAN Decreases Expression [43]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [36]
Protein PML (PML) OT6SM2GD PML_HUMAN Increases Expression [35]
Leukocyte elastase inhibitor (SERPINB1) OT5RDUFO ILEU_HUMAN Increases Expression [19]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [43]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [23]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Decreases Expression [44]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [40]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [45]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Decreases Expression [35]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [19]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Expression [46]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [47]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Increases Expression [23]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [24]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Decreases Phosphorylation [38]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [48]
ATP-citrate synthase (ACLY) OTRL9ZRP ACLY_HUMAN Increases Expression [24]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Increases Expression [24]
Nucleosome assembly protein 1-like 1 (NAP1L1) OTI7WBZV NP1L1_HUMAN Decreases Expression [19]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [32]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [34]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Increases Activity [30]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [34]
Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase (GCNT1) OTF6OC66 GCNT1_HUMAN Increases Expression [8]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Affects Activity [49]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Increases Expression [50]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [35]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [51]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Increases Expression [32]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Expression [24]
Integrin-linked protein kinase (ILK) OTYG2FD1 ILK_HUMAN Decreases Activity [38]
Endonuclease G, mitochondrial (ENDOG) OT5IM7B3 NUCG_HUMAN Affects Localization [25]
Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein (HERPUD1) OT9EROL6 HERP1_HUMAN Increases Expression [8]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Affects Localization [52]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [43]
Carbonic anhydrase 9 (CA9) OTNA51XT CAH9_HUMAN Decreases Expression [43]
Dehydrogenase/reductase SDR family member 11 (DHRS11) OTU3J0ZL DHR11_HUMAN Decreases Activity [53]
Protein NDRG1 (NDRG1) OTVO66BO NDRG1_HUMAN Increases Expression [35]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Decreases Expression [54]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [22]
Transmembrane 7 superfamily member 3 (TM7SF3) OTT9RKL6 TM7S3_HUMAN Decreases Expression [8]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Expression [24]
Serine/threonine-protein kinase TBK1 (TBK1) OT1P06NV TBK1_HUMAN Increases Expression [8]
Angiopoietin-related protein 3 (ANGPTL3) OTCD5Z9W ANGL3_HUMAN Decreases Expression [24]
eIF5-mimic protein 1 (BZW2) OTBT0A1B 5MP1_HUMAN Decreases Expression [8]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Increases Metabolism [55]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Affects Response To Substance [56]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Response To Substance [51]
------------------------------------------------------------------------------------
⏷ Show the Full List of 201 DOT(s)
Indication(s) of Idarubicin
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Acute myeloid leukaemia 2A60 Approved [5]
Adult acute monocytic leukemia N.A. Approved [4]
Childhood acute megakaryoblastic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Idarubicin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [58]
------------------------------------------------------------------------------------
Idarubicin Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [59]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [60]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [60]
------------------------------------------------------------------------------------
Idarubicin Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [61]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [61]
------------------------------------------------------------------------------------
Idarubicin Interacts with 9 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Decreases Activity [57]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [62]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Activity [57]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [63]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Decreases Activity [57]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [64]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Decreases Activity [57]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [65]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Decreases Activity [57]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Sulindac FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5425).
4 Idarubicin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
6 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
7 Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
8 Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer. 2000 Dec 15;88(6):873-80. doi: 10.1002/1097-0215(20001215)88:6<873::aid-ijc6>3.0.co;2-b.
9 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
10 Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
11 Fluo-cAMP is transported by multidrug resistance-associated protein isoform 4 in rat choroid plexus. J Neurochem. 2010 Oct;115(1):200-8.
12 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42.
13 Sulindac inhibited gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in T24 human bladder tumor cells. Urol Res. 2001 Dec;29(6):406-11.
14 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
15 Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003 Nov 28;278(48):47762-75.
16 Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
17 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
18 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
19 p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res. 2001 Aug 15;61(16):6297-302.
20 Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80. doi: 10.1093/jnci/djh322.
21 Sulindac induces apoptotic cell death in susceptible human breast cancer cells through, at least in part, inhibition of IKKbeta. Apoptosis. 2009 Jul;14(7):913-22. doi: 10.1007/s10495-009-0367-1.
22 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23 Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
24 Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
25 Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005 Sep 2;77(16):2059-70. doi: 10.1016/j.lfs.2005.04.021.
26 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
27 Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics. 2002 Oct 29;11(2):45-52. doi: 10.1152/physiolgenomics.00064.2002.
28 Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
29 Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
30 Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
31 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
32 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
33 The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB. Oncogene. 2008 Apr 17;27(18):2648-55. doi: 10.1038/sj.onc.1210891. Epub 2007 Dec 3.
34 Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
35 Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
36 Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. Oncol Rep. 2008 Aug;20(2):379-84.
37 JNK1 is required for sulindac-mediated inhibition of cell proliferation and induction of apoptosis in vitro and in vivo. Eur J Pharmacol. 2007 Apr 10;560(2-3):95-100. doi: 10.1016/j.ejphar.2007.01.020. Epub 2007 Jan 19.
38 Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
39 The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res. 2008 Oct 15;68(20):8269-77. doi: 10.1158/0008-5472.CAN-08-2010.
40 Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
41 Nonsteroidal anti-inflammatory drugs inhibit growth of human neuroendocrine tumor cells via G1 cell-cycle arrest. Int J Cancer. 2003 Dec 10;107(5):844-53. doi: 10.1002/ijc.11446.
42 Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
43 NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer. 2009 Jan 1;124(1):223-32. doi: 10.1002/ijc.23934.
44 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
45 Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol Sci. 2014 Jan;137(1):234-48. doi: 10.1093/toxsci/kft232. Epub 2013 Oct 17.
46 Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia. 2007 Mar;9(3):192-9. doi: 10.1593/neo.06781.
47 Sulindac induces apoptosis, inhibits proliferation and activates caspase-3 in Hep G2 cells. Anticancer Res. 2002 Jan-Feb;22(1A):263-6.
48 TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. J Pathol. 2011 Feb;223(3):378-89. doi: 10.1002/path.2797. Epub 2010 Oct 29.
49 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
50 Functional characterization of peroxisome proliferator-activated receptor-/ expression in colon cancer. Mol Carcinog. 2011 Nov;50(11):884-900. doi: 10.1002/mc.20757. Epub 2011 Mar 11.
51 Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
52 Sulindac-derived reactive oxygen species induce apoptosis of human multiple myeloma cells via p38 mitogen activated protein kinase-induced mitochondrial dysfunction. Apoptosis. 2007 Jan;12(1):195-209. doi: 10.1007/s10495-006-0527-5.
53 Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
54 Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 Feb 1;63(3):616-20.
55 Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 Dec 15;10(24):8357-62. doi: 10.1158/1078-0432.CCR-04-1073.
56 Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res. 2001 Dec;7(12):4000-7.
57 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
58 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
59 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
60 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
61 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
62 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
63 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
64 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
65 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.